围产期感染市场－全球产业规模、份额、趋势、机会和预测，按感染类型、治疗方法、诊断方法、最终用户、地区和竞争格局划分，2020-2030年预测

2024年全球围产期感染市场规模为16亿美元，预计2030年将以5.30%的复合年增长率成长至21.8亿美元。该市场专注于针对妊娠或分娩期间由母体传染给胎儿的病毒或细菌感染的诊断和治疗解决方案。市场扩张的主要驱动因素包括全球范围内此类感染盛行率的上升、医疗保健支出的增加以及公众对母婴健康意识的提高。诊断方法和治疗手段的持续技术进步，有助于更早发现感染并采取更有效的干预措施，从而进一步促进市场成长。

主要市场驱动因素

主要市场挑战

主要市场趋势

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球围产期感染市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依感染类型分类（鉅细胞病毒感染、肠病毒感染、生殖器疱疹、淋病、人类免疫缺乏病毒、李斯特菌病、淋巴球性脉络丛脑膜炎病毒、德国麻疹、梅毒、水痘、其他）
  • 依治疗方法分类（抗生素、抗病毒药物、抗病毒药物、其他）
  • 按诊断（母体检测、新生儿检测、其他）
  • 按最终使用者（医院和诊所、门诊中心、其他）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美围产期感染市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲围产期感染市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区围产期感染市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲围产期感染市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲围产期感染市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购（如有）
• 产品发布（如有）
• 最新进展

第十三章：全球围产期感染市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• Merck KGaA
• Beckman Coulter Inc.
• Bio-Rad Laboratories, Inc
• Hologic Inc.
• Gilead Sciences, Inc.
• Emcure Pharmaceuticals Limited.
• Cipla Inc.
• Bausch Health Companies Inc
• Johnson & Johnson
• Teva Pharmaceutical Industries Ltd.

第十六章：策略建议

第17章调查会社について・免责事项

The Global Perinatal Infections Market, valued at USD 1.6 Billion in 2024, is projected to experience a CAGR of 5.30% to reach USD 2.18 Billion by 2030. The Global Perinatal Infections Market focuses on diagnostic and therapeutic solutions for infections caused by viruses or bacteria transmitted from a mother to her fetus during gestation or childbirth. Market expansion is substantially driven by the increasing global prevalence of these infections, alongside rising healthcare expenditure and heightened public awareness concerning maternal and child health. Further growth is supported by continuous technological advancements in diagnostic methodologies and treatment modalities, facilitating earlier detection and more effective interventions.

Key Market Drivers

The Global Perinatal Infections Market is significantly shaped by sustained technological advancements in diagnostics and treatment. Innovations in diagnostic platforms are continuously enhancing the precision and accessibility of early detection for perinatal infections. This includes the development of non-invasive prenatal tests, which allow for screening of complex fetal genetic conditions with reduced risk. For instance, according to Natera, in August 2025, their Fetal Focus test, a noninvasive prenatal test for inherited conditions, was launched, supported by data from a clinical trial that initiated in 2023 and had enrolled approximately 1,300 participants. These diagnostic breakthroughs enable earlier and more accurate identification of infections, facilitating timely intervention and improving outcomes for both mother and child.

Key Market Challenges

The scarcity of adequately skilled healthcare professionals capable of providing accurate diagnosis and comprehensive treatment for complex perinatal conditions significantly impedes the growth of the Global Perinatal Infections Market. This shortage directly limits the effective deployment and utilization of innovative diagnostic technologies and therapeutic solutions. When there are insufficient trained personnel, particularly those specializing in infectious diseases, the ability to promptly and accurately identify perinatal infections is compromised. This often leads to delayed treatment initiation, reduced efficacy of available interventions, and poorer maternal and neonatal outcomes.

Key Market Trends

The growing adoption of personalized medicine approaches represents a pivotal trend reshaping the Global Perinatal Infections Market by moving beyond standardized treatments to highly individualized care. This trend emphasizes tailoring diagnostic and therapeutic interventions based on a mother's unique genetic profile, microbial resistance patterns, and immune response, aiming to optimize outcomes for both mother and child. Such customization drives demand for advanced molecular diagnostics capable of identifying specific pathogens and host genetic predispositions with high precision. According to the Personalized Medicine Coalition, the FDA approved 18 new personalized medicines in 2024, constituting 38% of all newly approved therapeutic molecular entities across various treatment areas. Companies are increasingly collaborating in this space; Roche and Janssen Biotech Inc. joined forces in February 2023 to develop personalized and targeted therapies alongside companion diagnostics, signaling a strategic focus on this tailored medical paradigm.

Key Market Players

• Merck KGaA
• Beckman Coulter Inc.
• Bio-Rad Laboratories, Inc
• Hologic Inc.
• Gilead Sciences, Inc.
• Emcure Pharmaceuticals Limited.
• Cipla Inc.
• Bausch Health Companies Inc
• Johnson & Johnson
• Teva Pharmaceutical Industries Ltd.

Report Scope:

In this report, the Global Perinatal Infections Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Perinatal Infections Market, By Infection Type:

• Cytomegalovirus Infection
• Enterovirus Infection
• Genital Herpes
• Gonorrhoea
• Human Immunodeficiency Virus
• Listeriosis Lymphocytic Choriomeningitis Virus
• Rubella
• Syphilis
• Varicella
• Others

Perinatal Infections Market, By Treatment:

• Antibiotics
• Antiviral
• Antiretroviral
• Others

Perinatal Infections Market, By Diagnosis:

• Maternal Test
• Neonatal Test
• Others

Perinatal Infections Market, By End user:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Perinatal Infections Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Perinatal Infections Market.

Available Customizations:

Global Perinatal Infections Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Perinatal Infections Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Infection Type (Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes, Gonorrhoea, Human Immunodeficiency Virus, Listeriosis Lymphocytic Choriomeningitis Virus, Rubella, Syphilis, Varicella, Others)
  • 5.2.2. By Treatment (Antibiotics, Antiviral, Antiretroviral, Others)
  • 5.2.3. By Diagnosis (Maternal Test, Neonatal Test, Others)
  • 5.2.4. By End user (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Perinatal Infections Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Infection Type
  • 6.2.2. By Treatment
  • 6.2.3. By Diagnosis
  • 6.2.4. By End user
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Perinatal Infections Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Infection Type
      • 6.3.1.2.2. By Treatment
      • 6.3.1.2.3. By Diagnosis
      • 6.3.1.2.4. By End user
  • 6.3.2. Canada Perinatal Infections Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Infection Type
      • 6.3.2.2.2. By Treatment
      • 6.3.2.2.3. By Diagnosis
      • 6.3.2.2.4. By End user
  • 6.3.3. Mexico Perinatal Infections Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Infection Type
      • 6.3.3.2.2. By Treatment
      • 6.3.3.2.3. By Diagnosis
      • 6.3.3.2.4. By End user

7. Europe Perinatal Infections Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Infection Type
  • 7.2.2. By Treatment
  • 7.2.3. By Diagnosis
  • 7.2.4. By End user
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Perinatal Infections Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Infection Type
      • 7.3.1.2.2. By Treatment
      • 7.3.1.2.3. By Diagnosis
      • 7.3.1.2.4. By End user
  • 7.3.2. France Perinatal Infections Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Infection Type
      • 7.3.2.2.2. By Treatment
      • 7.3.2.2.3. By Diagnosis
      • 7.3.2.2.4. By End user
  • 7.3.3. United Kingdom Perinatal Infections Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Infection Type
      • 7.3.3.2.2. By Treatment
      • 7.3.3.2.3. By Diagnosis
      • 7.3.3.2.4. By End user
  • 7.3.4. Italy Perinatal Infections Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Infection Type
      • 7.3.4.2.2. By Treatment
      • 7.3.4.2.3. By Diagnosis
      • 7.3.4.2.4. By End user
  • 7.3.5. Spain Perinatal Infections Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Infection Type
      • 7.3.5.2.2. By Treatment
      • 7.3.5.2.3. By Diagnosis
      • 7.3.5.2.4. By End user

8. Asia Pacific Perinatal Infections Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Infection Type
  • 8.2.2. By Treatment
  • 8.2.3. By Diagnosis
  • 8.2.4. By End user
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Perinatal Infections Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Infection Type
      • 8.3.1.2.2. By Treatment
      • 8.3.1.2.3. By Diagnosis
      • 8.3.1.2.4. By End user
  • 8.3.2. India Perinatal Infections Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Infection Type
      • 8.3.2.2.2. By Treatment
      • 8.3.2.2.3. By Diagnosis
      • 8.3.2.2.4. By End user
  • 8.3.3. Japan Perinatal Infections Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Infection Type
      • 8.3.3.2.2. By Treatment
      • 8.3.3.2.3. By Diagnosis
      • 8.3.3.2.4. By End user
  • 8.3.4. South Korea Perinatal Infections Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Infection Type
      • 8.3.4.2.2. By Treatment
      • 8.3.4.2.3. By Diagnosis
      • 8.3.4.2.4. By End user
  • 8.3.5. Australia Perinatal Infections Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Infection Type
      • 8.3.5.2.2. By Treatment
      • 8.3.5.2.3. By Diagnosis
      • 8.3.5.2.4. By End user

9. Middle East & Africa Perinatal Infections Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Infection Type
  • 9.2.2. By Treatment
  • 9.2.3. By Diagnosis
  • 9.2.4. By End user
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Perinatal Infections Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Infection Type
      • 9.3.1.2.2. By Treatment
      • 9.3.1.2.3. By Diagnosis
      • 9.3.1.2.4. By End user
  • 9.3.2. UAE Perinatal Infections Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Infection Type
      • 9.3.2.2.2. By Treatment
      • 9.3.2.2.3. By Diagnosis
      • 9.3.2.2.4. By End user
  • 9.3.3. South Africa Perinatal Infections Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Infection Type
      • 9.3.3.2.2. By Treatment
      • 9.3.3.2.3. By Diagnosis
      • 9.3.3.2.4. By End user

10. South America Perinatal Infections Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Infection Type
  • 10.2.2. By Treatment
  • 10.2.3. By Diagnosis
  • 10.2.4. By End user
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Perinatal Infections Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Infection Type
      • 10.3.1.2.2. By Treatment
      • 10.3.1.2.3. By Diagnosis
      • 10.3.1.2.4. By End user
  • 10.3.2. Colombia Perinatal Infections Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Infection Type
      • 10.3.2.2.2. By Treatment
      • 10.3.2.2.3. By Diagnosis
      • 10.3.2.2.4. By End user
  • 10.3.3. Argentina Perinatal Infections Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Infection Type
      • 10.3.3.2.2. By Treatment
      • 10.3.3.2.3. By Diagnosis
      • 10.3.3.2.4. By End user

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Perinatal Infections Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Merck KGaA
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Beckman Coulter Inc.
• 15.3. Bio-Rad Laboratories, Inc
• 15.4. Hologic Inc.
• 15.5. Gilead Sciences, Inc.
• 15.6. Emcure Pharmaceuticals Limited.
• 15.7. Cipla Inc.
• 15.8. Bausch Health Companies Inc
• 15.9. Johnson & Johnson
• 15.10. Teva Pharmaceutical Industries Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer